An observational study of fixed dose combination fluticasone propionate/salmeterol or fluticasone propionate alone on asthma-related outcomes

Current Medical Research and Opinion

Volumn 24, Issue 11, 2008, Pages 3141-3148

  Stanford, Richard H ^a   Fuhlbrigge, Anne ^b   Riedel, Aylin ^c   Rey, Gabriel Gomez ^c   Stempel, David A ^a  

^a GLAXOSMITHKLINE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c Health Economics and Outcomes ^*  (United States)

Author keywords

Asthma; Emergency medical services; Fluticasone propionate; Hospitalization; Salmeterol; Salmeterol combination; Utilization

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FLUTICASONE PROPIONATE; SALMETEROL;

ADULT; ARTICLE; ASTHMA; BILLING AND CLAIMS; CLINICAL EVALUATION; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE EXACERBATION; EMERGENCY WARD; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HOSPITAL PATIENT; HUMAN; INTUBATION; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MONOTHERAPY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PHARMACY; POPULATION; PREDICTION; PRESCRIPTION; RETROSPECTIVE STUDY; UNITED STATES;

ADOLESCENT; ADULT; ALBUTEROL; ANDROSTADIENES; ANTI-ALLERGIC AGENTS; ASTHMA; COHORT STUDIES; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; OBSERVATION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 67649411739     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990802462990     Document Type: Article

References (30)

1. Greenstone IR, Ni Chroinin MN, Masse V, et al. Combination of inhaled long-acting beta2-agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma. Cochrane Database Syst Rev 2005 Oct 19; CD005533. Review
2. Durcharme FM, Lasserson TJ, Cates CJ. Long-acting beta2- agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. Cochrane Database Syst Rev 2006 Oct 18;CD003137. Review
3. Masoli M, Weatherall M, Holt S, et al. Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroids in symptomatic asthma. Thorax 2005;60:730-734 (Pubitemid 41297891)
4. Stempel DA, O'Donnell JC, Meyer JW. Inhaled corticosteroids plus salmeterol or montelukast: effects on resource utilization and costs. J Allergy Clin Immunol 2002;109:433-439 (Pubitemid 34234192)
5. O'Connor RD, Carranza Rosenzweig JR, Stanford RH, et al. Asthma-related exacerbations, therapy switching, and therapy discontinuation: a comparison of three commonly used controller regimens. Ann Allergy Asthma Immunol 2005;95:535-540 (Pubitemid 43010479)
6. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Full Report 2007. National Heart, Lung, and Blood Institute, National Institutes of Health, National Heart, Lung, and Blood Institute. Available at http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm. Accessed June 17, 2008
7. Global Initiative for Asthma. Global strategy for asthma management and prevention. Updated 2007. Available at http://www.ginasthma.org. Accessed June 17, 2008
8. Nelson HS, Weiss ST, Bleecker ER, et al. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006;129:15-26 (Pubitemid 43265239)
9. Castle W, Fuller R, Hall J, et al. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 1993;306:1034-1037 (Pubitemid 23105961)
10. Anderson HR, Ayres JG, Sturdy PM, et al. Bronchodilator treatment and deaths from asthma: case-control study. BMJ 2005 Jan 15;330:117. Epub 2004 Dec 23 (Pubitemid 40138494)
11. American Lung Association Epidemiology & Statistics Unit Research Program Services. Trends in Asthma Morbidity and Mortality. November 2007. Available at: www.lungusa.org. Accessed June 17, 2008
12. Miniño AM, Heron MP, Smith BL. Deaths: preliminary data for 2004. Natl Vital Stat Rep 2006;54:1-49
13. DiSantostefano RL, Davis KJ, Yancey S, et al. Ecologic analysis of asthma-related events and dispensing of inhaled corticosteroid- and salmeterol-containing products. Ann Allergy Asthma Immunol 2008;100:558-565 (Pubitemid 351829854)
14. Bateman E, Nelson H, Bousquet J, et al. Meta-analysis: effects of adding salmeterol to inhaled corticosteroids on serious asthma-related events. Ann Intern Med 2008;149:33-42 (Pubitemid 351931131)
15. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000;342:1887-1892 (Pubitemid 30419054)
16. Avorn J. In defense of pharmacoepidemiology - embracing the yin and yang of drug research. N Engl J Med 2007;357:2219-2221
17. Benson K, Hartz A. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000;342:1878-1886 (Pubitemid 30419053)
18. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383 (Pubitemid 17055592)
19. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-619
20. SAS Institute, Inc., Cary, NC
21. StataCorp, LP, College Station, TX
22. Ni Chroinin M, Greenstone IR, Danish A, et al. Long-acting beta-2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma (review). Cochrane Database Syst Rev 2005 Oct 19;CD005535. Review
23. Kavuru M, Melamed J, Gross G, et al. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo- controlled trial. J Allergy Clin Immunol 2000;105:1108-1116 (Pubitemid 30418788)
24. Shapiro G, Lumry W, Wolfe J, et al. Combined salmeterol 50 μg and fluticasone propionate 250 μg in the Diskus device for the treatment of asthma. Am J Respir Crit Care Med 2000;161:527-534 (Pubitemid 30129463)
25. Weiss KB, Sullivan SD. The health economics of asthma and rhinitis. I. Assessing the economic impact. J Allergy Clin Immunol 2001;107:3-8
26. Ford JG, Meyer IH, Sternfels P, et al. Patterns and predictors of asthma-related emergency department use in Harlem. Chest 2001;120:1129-1135 (Pubitemid 32960082)
27. Griswold SK, Nordstrom CR, Clark S, et al. Asthma exacerbations in North American adults. Who are the "frequent fliers" in the emergency department? Chest 2005;127:1579-1586
28. Miller MK, Lee JH, Blanc PD, et al. TENOR risk score predicts healthcare in adults with severe or difficult-to-treat asthma. Eur Respir J 2006;28:1145-1155 (Pubitemid 44883849)
29. Miller MK, Lee JH, Miller DP, et al. Recent asthma exacerbations: a key predictor of future exacerbations. Respir Med 2007;101:481-489 (Pubitemid 46196331)
30. Suissa S. Immortal time bias in pharmacoepidemiology. Am J Epidemiol 2007;167:492-499 (Pubitemid 351264145)